SALONPAS ANALGESIC PATCH MONOGRAPH STATUS REQUIRES "SOME EVIDENCE"
This article was originally published in The Tan Sheet
SALONPAS ANALGESIC PATCH MONOGRAPH STATUS REQUIRES "SOME EVIDENCE" that the safety and efficacy of the active ingredients are not adversely affecting the product's patch delivery form, FDA Monograph Review Staff Deputy Director Gerald Rachanow said Oct. 4 at an "OTC feedback" meeting in Rockville, Md. "You have to have at least some evidence that you do not think that the patch is inhibiting the drug's effect," Rachanow advised Hisamitsu company representatives.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC